Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
Key Highlights
- ➤Collaboration targets alpha-lactalbumin commercial availability above 10 metric tonnes initially
- ➤Longer-term production target exceeds 200 metric tonnes annually
- ➤GRAS completion for bovine alpha-lactalbumin targeted for early 2028
- ➤Dyadic, BRIG BIO and Strive will develop and commercialize precision-fermented alpha-lactalbumin
Expert Statements
Joe Hazelton, President and Chief Operating Officer of Dyadic
“This collaboration is an important example of the commercialization strategy we are building around Dapibus.”
Joe Hazelton, President and Chief Operating Officer of Dyadic
“Our objective is not simply to demonstrate that Dapibus can produce commercially relevant proteins, but to work across the value chain to improve production economics, support scale-up and connect our technology with key partners, like BRIG BIO, that can help develop, manufacture, commercialize and ultimately use these products.”
Joe Hazelton, President and Chief Operating Officer of Dyadic
“Our work with BRIG BIO and the opportunity with Strive demonstrate how that model can create a pathway from technology development toward potential commercial demand.”
Steven Welle, Co-founder and CEO of BRIG BIO
“We believe precision-fermented alpha-lactalbumin has the potential to become an important next-generation nutrition ingredient.”
Steven Welle, Co-founder and CEO of BRIG BIO
“BRIG BIO brings precision-fermentation development and commercialization expertise to this collaboration, and our work with Dyadic is focused on further advancing the Dapibus strain and production process toward commercially viable manufacturing for high-value markets.”
Steven Welle, Co-founder and CEO of BRIG BIO
“Combining those capabilities with Strive’s product-development expertise and potential commercial application provides a realistic framework for moving alpha-lactalbumin from development toward market.”
Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp.
“Alpha-lactalbumin is an especially exciting protein because of its important role in human nutrition and its potential to help us develop better nutritional products.”
Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp.
“Although alpha-lactalbumin makes up only a small percentage of the total protein in cow’s milk, it is the predominant whey protein in human breast milk.”
Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp.
“Historically, obtaining this valuable protein from conventional dairy sources has required separating it from numerous other milk proteins, creating challenges for cost-effective production at scale.”
Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp.
“Working with Dyadic and BRIG BIO to produce alpha-lactalbumin directly through animal-free precision fermentation represents an exciting opportunity to improve access to this highly desirable ingredient.”
Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp.
“We see significant potential to incorporate alpha-lactalbumin into our FREEMILK™ platform and new, innovative Strive™ specialized nutrition products.”
Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp.
“Bovine alpha-lactalbumin is already a major component of children’s and adult nutritional products.”
JUPITER, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Corp. today announced a strategic collaboration aimed at advancing the development, scale-up and potential commercialization of precision-fermented bovine alpha-lactalbumin for Strive Nutrition’s FREEMILK™ platform and other Strive™ next-generation nutrition products.
The collaboration combines Dyadic’s Dapibus™ protein production platform and expertise in strain optimization and scale-up, BRIG BIO’s precision-fermentation commercialization and regulatory capabilities, and Strive’s FREEMILK™ platform and product-development and commercialization expertise. Together, the companies aim to advance the development and potential commercialization of precision-fermented alpha-lactalbumin for next-generation nutrition products.
Get started
Create a free account to read the full story.